December 26, 2013 – AstraZeneca and Shionogi & Co. Ltd. today announced the full resolution of arbitration proceedings related to the treatment of certain excise taxes and other specific items in the calculation of royalties on CRESTOR® sales. In addition, AstraZeneca and Shionogi & Co. Ltd. announced the extension of the global licence agreement for CRESTOR® […]
Conference Call to be Held at 9:00 a.m. Eastern Time, December 23, 2013 SILVER SPRING, Md., Dec. 20, 2013 /PRNewswire/ — United Therapeutics Corporation (NASDAQ: UTHR) announced today that the United States Food and Drug Administration (FDA) has approved Orenitram (treprostinil) Extended-Release Tablets for the treatment of pulmonary arterial hypertension (PAH) in WHO Group I patients to improve exercise capacity. “This […]
Upon approval, RoACTEMRA would be the first IL-6 biologic available in subcutaneous and intravenous administration for both monotherapy and combination therapy New subcutaneous formulation would offer greater flexibility for rheumatoid arthritis patients Basel, 20 December 2013 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the subcutaneous formulation of RoACTEMRA (tocilizumab) has received a positive […]
New Drug Application follows submission of Marketing Authorisation Application to the European Medicines Agency INDIANAPOLIS and RIDGEFIELD, Conn., Dec. 20, 2013 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of the New Drug Application (NDA) for LY2963016, an […]
Highlights Impact on Cost of Care SUNNYVALE, Calif., Dec. 19, 2013 (GLOBE NEWSWIRE) — A national, multi-institutional database study found readmission and complication rates were significantly lower for robotic-assisted prostate surgery than for open prostate surgery.1 The full study results were published in the November 19 electronic edition of the Journal of Endourology. “Readmissions for Medicare patients alone currently add $17.4 billion each year in […]
– Collaboration represents the first time the ACC’s PINNACLE Registry Research Alliance will be used for clinical trial recruitment – Paris, France and Tarrytown, New York – December 19, 2013 – Sanofi (EURONEXT : SAN and NYSE : SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ : REGN) announced today an innovative collaboration with the American College […]
Global agreement strengthens AstraZeneca’s commitment to diabetes, a key growth platform in a core strategic area for the company December 19 , 2013 – AstraZeneca today announced an agreement under which AstraZeneca will acquire the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance for an initial consideration of $2.7 billion on completion and up […]
New resources housed on T1EverydayMagic.com combine the expertise of Lilly Diabetes with the magic of Disney INDIANAPOLIS, Dec. 19, 2013 /PRNewswire/ — Lilly Diabetes and Disney today announced that their custom books for children and families with type 1 diabetes are now available online. The digital books explore real-life challenges and stories of children with […]
MALVERN, Pa. and MONTREAL, Dec. 19, 2013 /PRNewswire/ — Endo Health Solutions (NASDAQ: ENDP) (“Endo”) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR Act”) in connection with Endo’s proposed acquisition of Paladin Labs Inc. (TSX: PLB) (“Paladin Labs”) was terminated by the United States Federal Trade […]
NEW YORK– December 19, 2013 — (BUSINESS WIRE)–Forest Laboratories, Inc. (NYSE:FRX) announced today that FETZIMA™ (levomilnacipran ER capsules), is now available in pharmacies throughout the United States. FETZIMA was approved by the U.S. Food and Drug Administration (FDA) for the treatment of Major Depressive Disorder (MDD), also known as depression, in adults in July 2013. […]